Beijing Healthcare M&A Fund Completes Strategic Acquisition of Pediatrix Therapeutics to Forge Integrated 'Beijing Model'

On March 29, 2026, the Beijing Jingguoguan Yizhuang Kangqiao Medical Health M&A Investment Fund (hereinafter referred to as the “M&A Fund”) announced the completion of its strategic acquisition of Pediatrix Therapeutics. Following the acquisition, Dingfeng Biotech, a portfolio company of the M&A Fund, became the controlling shareholder of Pediatrix Therapeutics. This acquisition marks the M&A Fund’s follow-up to its successful acquisition of Eisai’s Pariet^®(Generic name: Rabeprazole Sodium) Following its business operations in China, this key strategic move in the specialized pharmaceutical sector represents another solid step toward building a full-cycle pharmaceutical and health industry platform.

The merger and acquisition (M&A) fund was established in partnership by QIAO Capital, Beijing State-owned Capital Operation and Management Co., Ltd. (“Beijing Guoguan”), and Beijing Yizhuang International Biomedical Investment Management Co., Ltd. (“Yizhuang Biomedical Platform Company”). Focusing on core sectors such as biopharmaceuticals, medical devices, and healthcare industry services, the fund leverages capital empowerment and industrial integration to promote the high-quality development of the healthcare industry in Beijing and the Beijing Economic-Technological Development Area. As the largest specialized healthcare M&A fund in China to date, it is managed by QIAO Capital, with QIAO Capital and Beijing Shunxi Private Equity Fund Management Co., Ltd. (“Shunxi Fund”) serving jointly as general partners.

Youer Pharma is an innovative pharmaceutical company focused on the field of pediatric therapeutics. Founded in 2021, the company has established a unique competitive advantage through its comprehensive capabilities in product selection, clinical development, regulatory approval, and commercialization. Currently, four products have been approved for market launch, with five additional pipeline products under development, covering multiple disease areas including neurology, allergies, and dermatology. Its core products include methylphenidate hydrochloride sustained-release dry suspension/chewable tablets for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, which commenced commercial sales in October 2024; and the world’s first epinephrine nasal spray for emergency treatment of severe acute allergic reactions, which was officially approved in mainland China in December 2025, significantly enhancing medication convenience and filling a gap in the out-of-hospital emergency care market. Many of the company’s core products are not only targeted at pediatric patients but also hold potential for expansion into adult indications. Against the backdrop of continuous growth in China’s pediatric drug market, where specialized medications remain relatively scarce, Youer Pharma has established a differentiated layout and a solid foundation for development in its niche sectors. The company is led by CEO Mr. Zhang Cheng, a seasoned pharmaceutical industry executive who previously served as Managing Director of Merck & Co. in China and Chief Operating Officer of Simcere Pharmaceutical Group, bringing over 25 years of experience in industry management and commercialization.

This acquisition strongly aligns with the M&A fund’s strategic vision of building a Beijing-based pharmaceutical industry platform. In the future, Youer Pharma will undergo deep integration with Dingfeng Biologics, which is controlled by the M&A fund, to construct a pharmaceutical platform anchored by mature products as a stable foundation and driven by an innovative pipeline as its core engine. Dingfeng Biologics has already established a mature commercialization team and sales network, while Youer Pharma complements the full “R&D–manufacturing–sales” value chain with its outstanding capabilities in product screening, research and development, and clinical development. Following integration, the two parties will achieve complementary capabilities and expand their therapeutic reach, extending from Dingfeng Biologics’ strong presence in gastroenterology and Youer Pharma’s focus on pediatrics to cover both adult and pediatric markets, thereby further expanding into multiple specialties including pediatrics, psychiatry, respiratory medicine, and dermatology.

This acquisition actively responds to the national and Beijing municipal policy orientations regarding the development of pediatric medications. In 2024, the National Health Commission issued the "Opinions on Promoting High-Quality Development of Pediatric Medical and Health Services," explicitly calling for efforts to "address shortcomings in pediatric drug availability." Beijing’s "Several Measures to Support the High-Quality Development of Innovative Pharmaceuticals (2025)" also proposes the development of "more convenient and safer novel drug delivery technologies for children." Youer Pharmaceutical’s product portfolio and innovation capabilities are highly aligned with these policy directions, injecting new momentum into the high-quality development of Beijing’s pharmaceutical and health industry.

This transaction also marks the secondary linkage between the Beijing Pharmaceutical and Health Industry Investment Fund and the M&A Fund, forming a “Industrial Fund + M&A Fund” dual-drive mechanism. The two-tiered municipal pharmaceutical funds will achieve strategic synergy to jointly empower the development of Beijing’s pharmaceutical and health industry.

Dingfeng Biologics will be responsible for the operational management of the integrated platform. By progressively building multi-wheel drive capabilities in “Business Development (BD) + R&D + Commercialization,” the integrated platform will evolve from a multi-product portfolio into a specialized platform covering the entire patient population within specific therapeutic areas, ultimately growing into a benchmark platform enterprise in Beijing’s pharmaceutical industry and driving industrial clustering.